Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia
Open Access
- 1 October 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (10) , 4128-4136
- https://doi.org/10.1128/aac.49.10.4128-4136.2005
Abstract
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel peptide deformylase inhibitor antimicrobial agent, for the treatment of M. pneumoniae pneumonia in a mouse model. Eight-week-old BALB/c mice were intranasally inoculated once with 10 7 CFU of M. pneumoniae . Groups of mice were treated with LBM415 (50 mg/kg of body weight) or placebo subcutaneously daily for 13 days, starting 24 h after inoculation. Groups of mice were evaluated at the baseline; at days of treatment 1, 3, 6, and 13; and at 7 days after treatment. The MIC of LBM415 against M. pneumoniae was M. pneumoniae concentrations than placebo-treated mice on days 6 and 13 of treatment. Compared with placebo treatment, therapy with LBM415 significantly decreased lung histopathology scores at days 3, 6, and 13 of treatment and at 7 days after treatment. Airway obstruction was significantly lower in LBM415-treated mice than in placebo-treated mice on days 1, 3, and 6 of treatment and after 7 days of therapy, while airway hyperresponsiveness was significantly lower only on day 3 of therapy. The bronchoalveolar lavage fluid concentrations of tumor necrosis factor alpha, gamma interferon (IFN-γ), interleukin-6 (IL-6), IL-12, KC (functional IL-8), monocyte chemotactic protein 1, macrophage inflammatory protein 1α, monokine induced by IFN-γ, and IFN-inducible protein 10 were significantly reduced in LBM415-treated mice compared with the levels in placebo-treated mice. There were no differences in the bronchoalveolar lavage fluid concentrations of granulocyte-macrophage colony-stimulating factor, IL-1β, IL-2, IL-4, IL-5, and IL-10 between the two groups of mice. LBM415 therapy had beneficial microbiologic, histologic, respiratory, and immunologic effects on acute murine M. pneumoniae pneumonia.Keywords
This publication has 45 references indexed in Scilit:
- Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other AgentsAntimicrobial Agents and Chemotherapy, 2004
- Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylaseClinical Microbiology & Infection, 2004
- Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolatesDiagnostic Microbiology and Infectious Disease, 2004
- Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolatesJournal of Antimicrobial Chemotherapy, 2004
- Mycoplasma pneumoniae: a reduced-genome intracellular bacterial pathogenInfection, Genetics and Evolution, 2003
- In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and UreaplasmasAntimicrobial Agents and Chemotherapy, 2003
- Severe Acute Lung Injury Caused byMycoplasma pneumoniae: Potential Role for Steroid Pulses in TreatmentClinical Infectious Diseases, 2000
- Fulminant Mycoplasma Pneumoniae Pneumonia with Marked Elevation of Serum Soluble Interleukin-2 Receptor.Internal Medicine, 1995
- Biochemical characterization of a gamma interferon-inducible cytokine (IP-10).The Journal of Experimental Medicine, 1987
- Current status of antibiotic treatment for Mycoplasma pneumoniae infectionsThe Pediatric Infectious Disease Journal, 1986